Blood test may personalize leukemia drug dosing

NCT ID NCT07670130

Recruiting now Knowledge-focused Sponsor: The First Affiliated Hospital of Soochow University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 4 times

Summary

This study looks at whether measuring the amount of venetoclax in the blood can help doctors give the right dose to people with newly diagnosed acute myeloid leukemia (AML). Currently, everyone gets the same dose, but drug levels vary a lot between patients. The goal is to find a blood concentration range that works best—boosting remission while limiting side effects like low blood counts. Fifty patients will be followed to see how drug levels relate to outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: venetoclax
What this could lead to: If successful, this could lead to personalized dosing of venetoclax for AML patients, potentially improving remission rates and reducing severe side effects.
What could go wrong: This is a small, early-phase study with only 50 participants, so results may not apply to all patients. The approach may not clearly improve outcomes over standard fixed dosing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMA ACUTE MYELOID LEUKEMIA (AML)

Contacts and locations

Locations

The first Affiliated Hospital of Soochow University
RECRUITING

Suzhou, 21500, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.